Telomir Pharmaceuticals (NASDAQ: TELO) has announced promising preclinical results for its lead candidate, Telomir-1, in treating Wilson’s disease, a rare genetic disorder characterized by excessive copper accumulation in the body. The study, conducted on zebrafish models mimicking human pathology, demonstrated Telomir-1's ability to significantly reduce tremors, normalize movement behaviors, and decrease liver copper levels by 50%. Additionally, the drug improved organ histopathology and restored key liver biomarkers to normal levels, alongside enhancing survival under copper stress.
The implications of these findings are profound for the approximately 1 in 30,000 individuals worldwide affected by Wilson’s disease. Currently, treatment options are limited and primarily focus on managing symptoms rather than addressing the underlying cause. Telomir-1's mechanism of action, which involves regulating copper levels and potentially lengthening telomeres, offers a novel approach that could transform the therapeutic landscape for this condition.
Telomir Pharmaceuticals is on track to file its first Investigational New Drug (IND) application by the end of the year, with human trials anticipated to begin in 2026. This development not only represents a significant milestone for the company but also underscores the potential of Telomir-1 to address unmet medical needs in the field of rare diseases and longevity science.
